Prevalence and factors associated with polypharmacy among people with multiple s...

연구 요약

Prevalence and factors associated with polypharmacy among people with multiple sclerosis (PwMS) receiving outpatient rehabilitation: A cross-sectional study.

Multiple sclerosis and related disorders 학술지에 발표된 이 연구는 Feng G, Scandiffio J, Law V 외 연구팀이 수행하였습니다.

이 연구는 'Prevalence and factors associated with polypharmacy among people with multiple sclerosis (PwMS) receiving outpatient rehabilitation: A cross-sectional study.'에 대한 과학적 분석을 제공합니다.

핵심 내용

BACKGROUND: Over 2.8 million people are living with multiple sclerosis (MS), many with comorbidities requiring pharmacologic intervention. This can lead to increased medication use and subsequent polypharmacy, which is associated with numerous adverse outcomes. The objective of this study is to describe medication use, the extent of polypharmacy, and correlates with sociodemographic, health behaviour and clinical/comorbidity factors in PwMS treated in an outpatient Physical Medicine and Rehabilitation (PM&R) setting. METHODS: This cross-sectional study uses retrospective chart data from all PwMS referred for rehabilitation at the largest MS tertiary care clinic in Canada between December 2021 and December 2023. Data on sociodemographic factors, clinical factors, and health service use were collected and analyzed using descriptive statistics and log-binomial regression modelling. RESULTS: A total of 475 PwMS were included, of which 343 (72.2%) had polypharmacy and 120 (25.2%) had hyper-polypharmacy (>10 concurrent medications). Most PwMS (62.3%, n = 296) were female, and the average age was 51.3 years (SD=11.8). PwMS with polypharmacy were taking an average of 8.9 medications (SD=3.5), compared to 3.0 on average (SD=1.1) among those without polypharmacy. Moreover, PwMS with polypharmacy had more comorbidities (median=3 vs 1, IQR=2-5 vs 1-3, p < 0.0001) than those without polypharmacy. Results from log-binomial logistic regression models found cannabinoid use (PR=1.43, 95% CI=1.25-1.64), physical comorbidities (PR=1.32, 95% CI=1.17-1.49), mental health comorbidities (PR=1.20, 95% CI=1.09-1.32), and cognitive symptoms (PR=1.15, 95% CI=1.02-1.30) to be associated with an increased prevalence of polypharmacy among PwMS. Full- or part-time employment was associated with a decreased prevalence of polypharmacy (PR=0.84, 95% CI=0.72-0.97). CONCLUSIONS: A high prevalence of polypharmacy was found among PwMS receiving rehabilitation. A variety of sociodemographic, behavioural, and clinical/comorbidity factors were associated with polypharmacy. Rehabilitation physicians treating PwMS should consider and address polypharmacy guided by established tools. Further research with a larger sample size and robust study design is needed to disentangle major risk factors and trajectories of polypharmacy among PwMS.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41713332)